DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewsWire • 06/09/26
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026GlobeNewsWire • 06/08/26
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewsWire • 06/05/26
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut AllergyGlobeNewsWire • 06/02/26
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NasdaqGlobeNewsWire • 05/12/26
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 04/24/26
DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN RevenueSeeking Alpha • 04/17/26
DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/14/26
Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should KnowZacks Investment Research • 04/14/26
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026GlobeNewsWire • 04/02/26
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration DocumentGlobeNewsWire • 03/26/26
DBV Technologies Reports Full Year 2025 Financial Results and Business UpdateGlobeNewsWire • 03/26/26
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual ReviewGlobeNewsWire • 03/24/26
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual MeetingGlobeNewsWire • 02/28/26
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual MeetingGlobeNewsWire • 02/10/26
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026GlobeNewsWire • 02/05/26
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 FinancingGlobeNewsWire • 01/16/26
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025GlobeNewsWire • 01/12/26
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025GlobeNewsWire • 01/05/26
DBV Launches, Up As Much As 46%, On A New Approach To Peanut AllergyInvestors Business Daily • 12/17/25